Home › Funds › Boussard & Gavaudan Investment Management LLP › ASND

Boussard & Gavaudan Investment Management LLP position in ASND

ASCENDIS PHARMA A/S · Health Care

Boussard & Gavaudan Investment Management LLP reported holding 12,900 shares of ASND (ASCENDIS PHARMA A/S) in its Q1 2026 13F filing — a position valued at US$18.8M, representing 2.07% of its reported portfolio and ranking #13 among its reported holdings. Boussard & Gavaudan Investment Management LLP has disclosed ASND holdings in 3 of the last 9 reported quarters, going back to Q1 2024.

Latest position (Q1 2026)12.90K sh
Reported value held$18.83M
Portfolio Weight2.07%
First reportedQ1 2024
Last changeAdd
Updated2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

How Boussard & Gavaudan Investment Management LLP's ASND position evolved

Boussard & Gavaudan Investment Management LLP first disclosed a stake in ASND in Q1 2024 at 6,000 shares (US$6.9M). The position peaked in Q1 2026 at 12,900 shares, worth US$18.8M. Across 3 filings, Boussard & Gavaudan Investment Management LLP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q1 2026) shows 12,900 shares valued at US$18.8M — an increase of 4,400 shares quarter over quarter.. Notable position changes include a 52% increase in Q1 2026 (shares rose 17% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 6.00K $6.92M New
Q4 2025 8.50K $11.95M New
Q1 2026 12.90K $18.83M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ASND and 13F data

ASND (ASCENDIS PHARMA A/S) is a Health Care company. 43 other funds we track also report a position in ASND — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$2.74B), T. Rowe Price Investment Management, Inc. (US$1.80B), Avoro Capital Advisors LLC (US$1.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ASND

All ASND fund holders →

FAQ

How long has Boussard & Gavaudan Investment Management LLP held ASND?

Boussard & Gavaudan Investment Management LLP has disclosed ASND holdings in 3 of the last 9 reported quarters, going back to Q1 2024.

What is Boussard & Gavaudan Investment Management LLP's current position in ASND?

As of Q1 2026, Boussard & Gavaudan Investment Management LLP holds 12.90K shares of ASND (ASCENDIS PHARMA A/S), valued at $18.83M, representing 2.07% of its reported portfolio and ranking #13.

Has Boussard & Gavaudan Investment Management LLP been buying or selling ASND?

In the latest 13F filing (Q1 2026), Boussard & Gavaudan Investment Management LLP increased its position in ASND. The position peaked in Q1 2026 at 12.90K shares.

Which other funds hold ASND?

Other major institutional holders of ASND include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.